Trial Profile
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Anselamimab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; First in man
- 06 Jun 2023 Results (n=22) assessing the long term efficacy and safety of CAEL-101 in patients with relapsed/refractory AL amyloidosis, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 14 Sep 2021 Results assessing tolerability and potential amyloidolytic effect of CAEL-101 in patients with light-chain amyloidosis, published in the Blood.
- 09 Nov 2020 According to a Fortress Biotech media release, positive long-term data from this trial were presented at the International Symposium on Amyloidosis (ISA) 2020.